Evolution of the Average Target: Outlook Therapeutics, Inc.

Evolution of the Average Target - Outlook Therapeutics, Inc.

Evolution of the Target Price: Outlook Therapeutics, Inc.

Evolution of the Target Price - Outlook Therapeutics, Inc.

Changes in Analyst Recommendations: Outlook Therapeutics, Inc.

89360536400993f78eb59.FI8qPpb2cMx1wQzxlksV34NNElLRy4S8Qg1hyCcbNJw.W7hyCMWCHYkQhjib5jMs6rsSUCP8ivLQFHg5-hFccPBsv0xK2sEhlUWCZw~b528f4f773e8a566ea692506496c21f7
18/05 BTIG Downgrades Outlook Therapeutics to Neutral From Buy MT
06/01 Chardan Adjusts Price Target on Outlook Therapeutics to $1 From $3, Maintains Neutral Rating MT
30/09/25 Outlook Therapeutics Plans to Resubmit ONS-5010 Biologics License Application Before Year-End MT
29/09/25 Outlook Therapeutics provides update on Type A Meeting with FDA RE
30/08/25 Outlook Therapeutics Shares Fall After HC Wainwright Downgrade MT
29/08/25 HC Wainwright Downgrades Outlook Therapeutics to Neutral From Buy, Adjusts Price Target to $1 From $3 MT
29/08/25 Guggenheim Downgrades Outlook Therapeutics to Neutral From Buy MT
02/12/24 Chardan Downgrades Outlook Therapeutics to Neutral From Buy, Puts Price Target 'Under Review' After $53 Price Target MT
27/03/24 BTIG Upgrades Outlook Therapeutics to Buy From Neutral, Price Target at $50 MT
16/02/24 Chardan Upgrades Outlook Therapeutics to Buy From Neutral, $3 Price Target; Says Risk/Reward is Favorable for Lytenava BLA Resubmission MT
16/02/24 Chardan Upgrades Outlook Therapeutics to Buy From Neutral, $3 Price Target MT
26/01/24 Guggenheim Upgrades Outlook Therapeutics to Buy From Neutral, Sets Price Target at $2 MT
26/01/24 Brookline Capital Upgrades Outlook Therapeutics to Buy From Hold, Price Target is $1.57 MT
28/12/23 Capital One Upgrades Outlook Therapeutics to Overweight From Equalweight With $5 Price Target MT
31/08/23 Chardan Downgrades Outlook Therapeutics to Neutral From Buy MT
31/08/23 HC Wainwright Downgrades Outlook Therapeutics to Neutral From Buy, Price Target is $1 MT
31/08/23 Brookline Capital Downgrades Outlook Therapeutics to Hold From Buy MT
31/08/23 Cantor Fitzgerald Downgrades Outlook Therapeutics to Neutral From Overweight, Adjusts Price Target to $1 From $4.50 MT
31/08/23 BTIG Downgrades Outlook Therapeutics to Neutral From Buy MT
14/07/23 Capital One Initiates Outlook Therapeutics With Overweight Rating, $5 Price Target MT
04/04/23 Guggenheim Initiates Outlook Therapeutics at Buy With $5 Price Target MT
07/02/23 Cantor Fitzgerald Initiates Outlook Therapeutics at Overweight With $4 Price Target MT
07/01/23 HC Wainwright Adjusts Price Target on Outlook Therapeutics to $5 From $6, Maintains Buy Rating MT
01/11/22 BTIG Starts Outlook Therapeutics at Buy With $7 Price Target MT
13/09/22 Chardan Capital Starts Outlook Therapeutics at Buy With $10 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+866.35%
+29.95%
+11.46%
+29.38%
+12.36%
+13.51%
+31.18%
+35.68%
+20.18%
+6.68%
Average +105.67%
Weighted average by Cap. +22.34%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.5200USD
Average target price
5.025USD
Spread / Average Target
+866.35%
High Price Target
10.50USD
Spread / Highest target
+1,919.23%
Low Price Target
1.600USD
Spread / Lowest Target
+207.69%

Analyst Consensus Detail

Analyst consensus - Outlook Therapeutics, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Outlook Therapeutics, Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Outlook Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. OTLK Stock
  4. Consensus Outlook Therapeutics, Inc.